UPDATED WORLD HEALTH ORGANIZATION CLASSIFICATION OF MYELOID NEOPLASMS AND ACUTE LEUKEMIAS (2016 REVISION)
Keywords:
myeloid neoplasms, acute leukemias, classification, translocations.Abstract
Summary. The principal provisions of the 2016 revision
to the World Health Organization classification of myeloid neoplasms and acute leukemia, namely revisions to
the categories of myeloid neoplasms and acute leukemia
have been considered. The major changes in the classification have been presented as compared with WHO
classification of tumors of hematopoietic and lymphoid
tissues published in 2008. The principal forms of myeloproliferative neoplasms and acute leukemia according to
the revised classification have been listed and the major criteria for their diagnosis have been considered.
The disease entities are defined based on histogenetic
principles for ascertaining the lineage of the transformed
cells and their differentiation level taking into account
the recent findings on the cytogenetic and molecular biological abnormalities in the blast cells. The use of the
revised classification allows one for diagnosing precisely myeloid neoplasms and acute leukemia contributing
to the improvement of their therapies.
References
Jaffe ES, Harris NL, Stein H, Vardiman YW (eds). Pathology and genetics of haematopoietic and lymphoid tissues. Lyon:
IARC Press, 2001. 351 p.
Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008. 439 p.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405.
Deininger MW. Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book 2015; 35:
e381–e388.
Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28 (7): 1407–13.
Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117 (21): 5710–18.
Gianelli U, Bossi A, Cortinovis I, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome negative myeloproliferative neoplasms. Mod Pathol 2014; 27 (6): 814–22.
Schuler E, Schroeder M, Neukirchen J, et al. Refined medullary blast and white blood cell count based classification of
chronic myelomonocytic leukemias. Leuk Res 2014; 38 (12): 1413–9.
Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 2015; 125 (3): 499–503.
Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015; 29 (1): 66–75.
Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28 (2): 241–7.
Kwok B, Hall JM, Witte JS, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126 (21): 2355–61.
Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119 (24): 5674–77.
Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3) (q21;q26) by activating EVI1 expression. Cancer Cell 2014; 25 (4): 415–27.
Konoplev S, Yin CC, Kornblau SM, et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 2013; 54 (1): 138–44.
Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29 (10): 1364–72.
Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009; 114 (14): 3024–32.
Churpek JE, Marquez R, Neistadt B, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 2016; 122 (2): 304–11.
Shimizu H, Yokohama A, Hatsumi N, et al. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol 2014; 93 (4): 297–301.
Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinaseactivating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371 (11): 1005–15.
Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10 (2): 147–56.
Neumann M, Heesch S, Schlee C, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013; 121 (23): 4749–52
